XT
CBIO

XTX Topco’s Crescent Biopharma CBIO Stock Holding History

XTX Topco’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190K Buy
+10,564
New +$206K ﹤0.01% 3281
2025
Q1 		– Sell
-642
Closed -$16K – 2640
2024
Q4 		$16K Buy
642
+393
+158% +$10.7K ﹤0.01% 2080
2024
Q3 		$4.21K Buy
+249
New +$5.22K ﹤0.01% 1984
2024
Q1 		– Sell
-111
Closed -$26.2K – 2017
2023
Q4 		$26.2K Sell
111
-216
-66% -$33.6K 0.01% 1329
2023
Q3 		$49.1K Buy
327
+27
+9% +$4.26K 0.01% 1282
2023
Q2 		$52.2K Buy
+300
New +$50.3K 0.01% 1234
2023
Q1 		– Sell
-636
Closed -$193K – 1422
2022
Q4 		$193K Buy
+636
New +$93.8K 0.04% 860
2021
Q3 		– Sell
-590
Closed -$137K – 812
2021
Q2 		$137K Buy
+590
New +$150K 0.05% 620

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

XTX Topco's CBIO Position: Q2 2026 in Review

XTX Topco opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 10,564 shares worth $190K. The stake represents ﹤0.01% of the portfolio and ranks #3281 among its holdings. This is a return to the name: XTX Topco previously reported a position in CBIO as recently as Q4 2024.

XTX Topco first reported a position in CBIO in Q2 2021 and has held it in 8 quarters since. The position peaked at $193K in Q4 2022. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • XTX Topco held 10,564 shares of Crescent Biopharma worth $190K as of Q2 2026.
  • Crescent Biopharma was a new XTX Topco position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3281 holding.
  • XTX Topco first reported a position in Crescent Biopharma in Q2 2021 and has held it in 8 quarters since.
  • XTX Topco's Crescent Biopharma position peaked at $193K in Q4 2022.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.